Bone Histomorphometry in Renal Osteodystrophy

Seminars in Nephrology

Volumn 29, Issue 2, 2009, Pages 122-132

  Ott, Susan M ^a  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

CKD; Improving Global Outcomes; mineralization; osteoblasts; osteoclasts; osteocytes; renal osteodystrophy; turnover; volume (TMV)

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE;

ARTICLE; BONE BIOPSY; BONE DENSITY; BONE MINERALIZATION; CHRONIC KIDNEY DISEASE; CLINICAL EVALUATION; CLINICAL FEATURE; DISEASE COURSE; HUMAN; MINERAL METABOLISM; MORPHOMETRICS; OSSIFICATION; OSTEOLYSIS; OSTEOMALACIA; PARATHYROID HORMONE BLOOD LEVEL; PATHOPHYSIOLOGY; POROSITY; PREVALENCE; PRIORITY JOURNAL; RENAL OSTEODYSTROPHY;

ANIMALS; BONE AND BONES; BONE REMODELING; DISEASE PROGRESSION; HUMANS; KIDNEY FAILURE, CHRONIC; RENAL OSTEODYSTROPHY;

EID: 64049084528     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2009.01.005     Document Type: Article

References (31)

1. Moe S., Drueke T., and Cunningham J. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 69 (2006) 1945-1953
2. Ott S. Histomorphometric analysis of bone remodeling. In: Bilezikian J., Raisz L., and Ga R. (Eds). Principles of bone biology (2002), Academic Press, San Diego 303-320
3. Parfitt A.M. Osteonal and hemi-osteonal remodeling: the spatial and temporal framework for signal traffic in adult human bone. J Cell Biochem 55 (1994) 273-286
4. Robling A.G., Niziolek P.J., Baldridge L.A., et al. Mechanical stimulation of bone in vivo reduces osteocyte expression of sost/sclerostin. J Biol Chem 283 (2008) 5866-5875
5. Eriksen E.F., Gundersen H.J.G., Melsen F., and Mosekilde L. Reconstruction of the formative site in iliac trabecular bone in 20 normal individuals employing a kinetic model for matrix and mineral apposition. Metab Bone Dis Rel Res 5 (1984) 243-252
6. Jowsey J. Age changes in human bone. Clin Orthop Rel Res 17 (1960) 210-217
7. Osteoporosis and Bone Physiology [cited 2009 Feb 5]. Available from: http://courses.washington.edu/bonephys.
8. Recker R.R., Lappe J.M., Davies K.M., and Heaney R.P. Bone remodeling increases substantially in the years after menopause and remains increased in older osteoporosis patients. J Bone Miner Res 19 (2004) 1628-1633
9. Parfitt A.M. Osteomalacia and related disorders. In: Aviolo L., and Krane S.M. (Eds). Metabolic bone disease (1990), Saunders, Philadelphia 329-396
10. Lindergard B., Johnell O., Nilsson B.E., and Wiklung P.E. Studies of bone morphology, bone densitometry, and laboratory data in patients on maintenance hemodialysis treatment. Nephron 39 (1985) 122-129
11. Chavassieux P.M., Arlot M.E., and Meunier P.J. Intersample variation in bone histomorphometry: comparison between parameter values measured on two contiguous transiliac bone biopsies. Calcif Tissue Int 37 (1985) 345-350
12. Baker L.R., Muir J.W., Sharman V.L., et al. Controlled trial of calcitriol in hemodialysis patients. Clin Nephrol 26 (1986) 185-191
13. Ferreira A., Frazao J.M., Monier-Faugere M.C., et al. Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. J Am Soc Nephrol 19 (2008) 405-412
14. Freemont A.J., Hoyland J.A., and Denton J. The effects of lanthanum carbonate and calcium carbonate on bone abnormalities in patients with end-stage renal disease. Clin Nephrol 64 (2005) 428-437
15. Hamdy N.A., Kanis J.A., Beneton M.N., et al. Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ 310 (1995) 358-363
16. Nordal K.P., and Dahl E. Low dose calcitriol versus placebo in patients with predialysis chronic renal failure. J Clin Endocrinol Metab 67 (1988) 929-936
17. Sanchez C., Lopez-Barea F., Sanchez-Cabezudo J., et al. Low vs standard calcium dialysate in peritoneal dialysis: differences in treatment, biochemistry and bone histomorphometry. A randomized multicentre study. Nephrol Dial Transplant 19 (2004) 1587-1593
18. Spasovski G.B., Sikole A., Gelev S., et al. Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up. Nephrol Dial Transplant 21 (2006) 2217-2224
19. Malluche H.H., Siami G.A., Swanepoel C., et al. Improvements in renal osteodystrophy in patients treated with lanthanum carbonate for two years. Clin Nephrol 70 (2008) 284-295
20. Joffe P., Heaf J.G., and Hyldstrup L. Osteocalcin: a non-invasive index of metabolic bone disease in patients treated by CAPD. Kidney Int 46 (1994) 838-846
21. Piraino B., Chen T., Cooperstein L., Segre G., and Puschett J. Fractures and vertebral bone mineral density in patients with renal osteodystrophy. Clin Nephrol 30 (1988) 57-62
22. Araujo S.M., Ambrosoni P., Lobao R.R., et al. The renal osteodystrophy pattern in Brazil and Uruguay: an overview. Kidney Int Suppl 85 (2003) S54-S56
23. Gerakis A., Hadjidakis D., Kokkinakis E., Apostolou T., Raptis S., and Billis A. Correlation of bone mineral density with the histological findings of renal osteodystrophy in patients on hemodialysis. J Nephrol 13 (2000) 437-443
24. Torres A., Lorenzo V., and Gonzalez-Posada J.M. Comparison of histomorphometry and computerized tomography of the spine in quantitating trabecular bone in renal osteodystrophy. Nephron 44 (1986) 282-287
25. Van Eps C.L., Jeffries J.K., Anderson J.A., et al. Mineral metabolism, bone histomorphometry and vascular calcification in alternate night nocturnal haemodialysis. Nephrology (Carlton) 12 (2007) 224-233
26. DeVita M.V., Rasenas L.L., Bansal M., et al. Assessment of renal osteodystrophy in hemodialysis patients. Medicine (Baltimore) 71 (1992) 284-290
27. Haas M., Leko-Mohr Z., Roschger P., et al. Osteoprotegerin and parathyroid hormone as markers of high-turnover osteodystrophy and decreased bone mineralization in hemodialysis patients. Am J Kidney Dis 39 (2002) 580-586
28. Hutchison A.J., Whitehouse R.W., Boulton H.F., Adams J.E., Mawer E.B.F., and Gokal R. Correlation of bone histology with parathyroid hormone, vitamin D3, and radiology in end-stage renal disease. Kidney Int 44 (1993) 1071-1077
29. Schober H.C., Han Z.H., Foldes A.J., et al. Mineralized bone loss at different sites in dialysis patients: implications for prevention. J Am Soc Nephrol 9 (1998) 1225-1233
30. Boling E., Primavera C., Friedman G., King M., Bosserman L.S.E., and Goodman W.G. Non-invasive measurements of bone mass in adult renal osteodystrophy. Bone 14 (1993) 409-413
31. Fletcher S., Jones R.G., Rayner H.C., et al. Assessment of renal osteodystrophy in dialysis patients: use of bone alkaline phosphatase, bone mineral density and parathyroid ultrasound in comparison with bone histology. Nephron 75 (1997) 412-419